Stockwinners Market Radar for September 29, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EDT Rogers Communications names Paulina Molnar as interim CFO - Rogers Communications announced that Tony Staffieri, the company's CFO, is leaving Rogers effective September 29, 2021. Paulina Molnar has been appointed interim CFO. She has been with Rogers for 16 years and is currently Senior Vice President, Controller and Risk Management.

19:09 EDT Vir Biotech saw significant progress on global patient access to sotrovimab - In a regulatory filing earlier, Vir Biotechnology "announced significant progress increasing global patient access to sotrovimab, an investigational monoclonal antibody treatment for COVID-19 developed in partnership with GlaxoSmithKline. To date, binding agreements have been received for the sale of more than 420,000 doses of sotrovimab worldwide, including a portion of those procured by the U.S. government. In addition, more than 220,000 doses have been reserved through other agreements. The companies continue discussions with governments around the world for additional agreements that can support the ongoing pandemic response."

18:41 EDT Liberty Oilfield Services CFO sells 154K shares of common stock - In a regulatory filing, Liberty Oilfield Services disclosed that its CFO Michael Stock sold 154K shares of common stock on September 28th in a total transaction size of $2.0M, reducing his stake by about 14%.

18:24 EDT Micron CEO: FY22 will be a record year with solid profitability - In an interview on CNBC's Mad Money, Sanjay Mehrotra said Micron is managing through the challenges of the pandemic very well. The company is focused on driving differentiated solutions and its execution is "rock solid," he noted. Micron is at the leading edge of memory and storage solutions, he added. The company's balance sheet is strong and inventory levels are lower than targeted due to the surge in demand, he said. Overall, inventories are running lean industry-wide, according to Mehrotra.

18:11 EDT B&G Foods issues voluntary recall of cases ofTone's Taco Seasoning Blend - B&G Foods is voluntarily recalling 3,867 cases of 23 oz. Tone's Taco Seasoning Blend, with "best by" dates of SEPT 03 24 and SEPT 06 24, due to the presence of undeclared wheat. A portion of the individual containers within those cases were mistakenly labeled on the back with the back labels for Tone's Lemon Pepper Seasoning Blend, which does not list wheat as an allergen. People who have an allergy or severe sensitivity to wheat run the risk of serious or life-threatening allergic reaction if the recalled product is consumed. There is no health risk associated with this product for individuals without an allergy or severe sensitivity to wheat. This recall does not apply to any other "best by" dates, sizes or varieties of Tone's brand products. No allergic reactions or consumer complaints related to this matter have been reported to date. This recall was initiated in cooperation with the FDA.

17:52 EDT Evergy director buys 39.6K shares of common stock - In a regulatory filing, Evergy disclosed that its director John Wilder bought 39.6K shares of common stock on September 28th in a total transaction size of $2.49M.

17:30 EDT Twitch debuts new features to restrain 'hate raid' attacks - "Hate and harassment of any kind is unacceptable and prohibited on Twitch, whether it's an offensive message, malicious follows, or the egregious "hate raid" attacks that have targeted marginalized creators over the past months. Curbing this type of behavior is, and will continue to be, a top priority for us. While we have tools available to help creators protect themselves, we know there will always be more to be done to stop hateful behavior, especially by motivated individuals and groups. Today, we're updating our suite of moderation tools by adding phone-verified chat and expanding the settings for email verification, to help Creators better control their chat experience and improve security. This will be available to all Creators starting today, and can be accessed from your Creator Dashboard," said the live streaming video platform and community for gamers in a blog post. Twitch was bought by Amazon in 2014. Reference Link

17:22 EDT Raytheon Technologies awarded $358.03M Navy contract - Raytheon was awarded a $358.03M firm-fixed-price contract in support of the fiscal 2021-2023 Evolved Seasparrow Missile, or ESSM, Block 2 full rate production requirements. The ESSM program is an international cooperative effort to design, develop, test, and procure ESSM missiles. The ESSM provides enhanced ship defense. This contract includes options which, if exercised at the maximum quantities, would bring the cumulative value of this contract to $1.28B. This contract combines purchases for the Navy and the governments of Canada, Australia, Greece, Germany, Norway, Turkey, Portugal, Belgium, the Netherlands, and Denmark under the NATO Seasparrow Consortium. Work is expected to be completed by March 2025. If all options are exercised, work will continue through March 2027. FY21 other customer funds in the amount of $189.27M; FY21 weapons procurement funds in the amount of $156.14M and FY20 other customer funds in the amount of $12.62M, will be obligated at time of award and will not expire at the end of the current fiscal year. This contract was not competitively procured in accordance with 10 U.S. Code 2304 international agreement between the U.S. and a foreign government or international organization. The Naval Sea Systems is the contracting activity.

17:17 EDT Virgin Galactic cleared to fly following conclusion of FAA inquiry - Virgin Galactic Holdings announced that it is cleared to fly FAA-licensed spaceflights following the conclusion of an FAA inquiry that focused on air traffic control clearance and real-time mission notification related to the Unity 22 flight in July. The FAA advised Virgin Galactic that the corrective actions proposed by the company have been accepted and conclude the FAA inquiry, which began August 11. They include updated calculations to expand the protected airspace for future flights, designating a larger area will ensure that Virgin Galactic has ample protected airspace for a variety of possible flight trajectories during spaceflight missions, and additional steps into the company's flight procedures to ensure real-time mission notifications to FAA Air Traffic Control. Virgin Galactic CEO Michael Colglazier said: "Our entire approach to spaceflight is guided by a fundamental commitment to safety at every level, including our spaceflight system and our test flight program. We appreciate the FAA's thorough review of this inquiry. Our test flight program is specifically designed to continually improve our processes and procedures. The updates to our airspace and real-time mission notification protocols will strengthen our preparations as we move closer to the commercial launch of our spaceflight experience." Virgin Galactic said that it continues to focus on its pre-flight readiness for Unity 23.

17:16 EDT Churchill Downs announces new $500M share buyback program - Churchill Downs announced that the board approved a $500M share repurchase program. The new share repurchase program replaces the prior $300M program that was authorized in October 2018 and had unused authorization of $97.9 million as of September 29, 2021. The new share repurchase program includes and is not in addition to any unspent amount remaining under the prior authorization.

17:05 EDT Fortis increases quarterly dividend 6% - The board of Fortis declared a common share dividend of 53.5c per share on the issued and outstanding fully paid common shares of the corporation, representing an approximate 6% increase in the quarterly dividend, payable on December 1 to the common shareholders of record at the close of business on November 17, marking 48 consecutive years of increased dividends. Fortis' dividend increase is in line with the corporation's guidance of 6% average annual dividend growth through 2025.

17:03 EDT Conformis reports 98.5% implant survivorship using iTotal CR knee replacement - Conformis "announced the strong results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR knee replacement implant, which assessed implant survivorship, patient satisfaction, and functional outcomes. he primary results of the clinical study include Implant Survivorship at 98.5%, with 8 revisions representing 1.5% of the 540 implants reviewed at a mean follow-up of 2.8 years and Patient Satisfaction of 89% reported being either satisfied or highly satisfied".

17:01 EDT IDT Corp subsidiary sells minority stake to Alta Fox Capital for $10M - IDT Corporation announced that its National Retail Solutions, NRS, subsidiary has concluded the sale of a 2.5% stake for $10M to Alta Fox Capital Management, a private investment fund based in Fort Worth, Texas.

17:00 EDT Cabot Oil & Gas and Cimarex Energy shareholders approve merger - Cabot Oil & Gas (COG) and Cimarex Energy (XEC) shareholders voted to approve the pending transaction. More than 99% of Cabot shareholders voted shares were in favor of the merger. More than 90% of Cimarex shareholders voted in favor of the merger. The transaction is anticipated to close on October 1. Following the closing of the transaction, the combined business intends to change its name and ticker symbol. Cimarex and Cabot entered into a definitive agreement on May 23 whereby the companies will combine in an all-stock transaction. Under the terms of the definitive agreement, each eligible share of Cimarex common stock issued and outstanding immediately prior to the effective time of the transaction will be exchanged for 4.0146 shares of Cabot common stock

16:31 EDT Ross Stores names Adam Orvos as CFO, effective October 1 - Ross Stores (ROST) announced that Adam Orvos, currently Group Senior Vice President, Supply Chain Administration, is being promoted to Executive Vice President and CFO effective October 1. In his new role, Orvos will be responsible for the company's accounting, treasury, financial planning, tax, corporate social responsibility, and investor relations functions. As CFO, he will report to Michael Hartshorn, Group President and COO. Orvos joined Ross Stores in January 2021 as Group Senior Vice President, Supply Chain Administration. His 34 years of broad-based retail management experience includes serving as CFO for Neiman Marcus, Belk Department Stores, and the Foley's Division of The May Department Stores Company. He has also held senior executive roles at Lowe's and Total Wine & More.

16:23 EDT ViacomCBS, Pluto to pay $3.5M penalty to settle FCC accessibility investigation - The Federal Communications Commission's Enforcement Bureau announced it has settled an investigation with Pluto Inc. and its parent company, ViacomCBS Inc., regarding violations of the Commission's accessibility rules. In addition to paying a $3.5M civil penalty, Pluto Inc. agreed to enter into a compliance plan to ensure that non-exempt video programming that Pluto streams over the internet includes closed captioning in compliance with Commission rules. Today's action reflects the first consent decree and first enforcement action related to Internet Protocol closed captioning rules since their adoption in 2012.

16:16 EDT OGE Energy increases quarterly dividend to 41c per share - OGE Energy has approved an increase in the company's quarterly dividend to 41c per share from 40.25c per share, which equates to $1.64 per share annually. The increase will be paid Oct. 29 to shareholders of record Oct. 12.

16:15 EDT Great Lakes Dredge announces partnership with Project Vesta - Great Lakes Dredge announced a partnership with Project Vesta. Known as "Coastal Carbon Capture", Project Vesta's method accelerates the earth's natural carbon removal process by using a natural rock turned into carbon-removing sand. According to a report by the National Academy of Sciences, this technique has the potential to remove billions of tons of carbon dioxide from the atmosphere and reduce ocean acidification.

16:13 EDT Ford renews $15.5B in revolving corporate credit lines - Ford announced the extension of $15.5B in revolving credit lines, which now include metrics that "further align the company's financing actions with its commitment to operate a safe, sustainable and successful business - elements that are fundamental to the Ford+ plan for growth and value creation." The arrangement comprises extensions of three revolving credit lines: a five-year, $10.1B facility maturing in September 2026, along with a three-year, $3.4B facility and a three-year, $2B supplemental facility, both maturing in September 2024. "Ford people recognize that what's good for the planet is good for business," said Dave Webb, the company's treasurer. "We're all accountable for creating a constantly safer and cleaner organization that sets an example for sustainability."

16:13 EDT Aurora Cannabis launches its first medical CBD product in Uruguay - Aurora Cannabis has launched Bidiol, the first medical cannabis oil in Uruguay that is wholly produced domestically. The CBD oil is available in pharmacies across the country. Aurora has shifted its strategy in Uruguay to focus exclusively on medical cannabis, with the aim of making the country its continental centre of production and distribution. Aurora's operation in Uruguay includes one of the only GMP certified cannabis processing facilities in the country. CBD oil is authorized by the Ministry of Public Health of Uruguay for the treatment of refractory epilepsy in children and adolescents. Aurora is continuing to develop its CBD oil product line in Uruguay, with plans to expand its portfolio in the coming months.

16:11 EDT Herman Miller reports Q1 orders $916.5M, up 64.8% - Strong demand and the Knoll acquisition drove quarterly orders of $916.5M, an increase of 64.8% compared to the prior year period, up 34.5% organically.

16:10 EDT Kforce signs lease for new headquarters in Tampa - Kforce announced that they have signed a lease for its new headquarters in Midtown Tampa. Kforce is proud to have honored its commitment to stay in Tampa. The Firm will occupy the fifth floor of Midtown West, one of four office buildings planned for the22-acre, $500M mixed-usedevelopment.The 10-year-lease goes into effect October 2022.

16:08 EDT Eagle Bancorp increases cash dividend 14% to 40c per share - Eagle Bancorp announced a cash dividend for Q3 in the amount of 40c per share. The cash dividend will be payable on November 1 to shareholders of record on October 21. This represents an increase of 5c per share, or 14%, from the dividend paid of 35c per share for Q2 and an increase of 18c per share, or 82%, from the 22c per share for the third quarter of 2020.

16:07 EDT ICF International selected for $150M contract by National Cancer Institute - ICF has been selected by The National Institutes of Health's National Cancer Institute as one of three awardees for a new multiple-award indefinite delivery, indefinite quantity - IDIQ - contract to provide biomedical technical and data management support services. The ICF contract has a ceiling value of $150M and a term of five years. Services include communications and web support, data management, cloud-native biomedical computing, analytics and engineering, biomedical computing platform and tool development, bioinformatics, statistical modeling and analysis, and technical, administrative and project management support.

16:06 EDT Orion Group awarded $192M in contracts - Orion Group announced two contract awards for its Marine segment totaling nearly $200M. The Company has been awarded a contract valued at approximately $125M from the Florida Department of Transportation to replace the State Road 405 Indian River Bridge over the NASA Causeway near Cape Canaveral, Florida. This bridge provides the main access to Kennedy Space Center and Cape Canaveral Space Force Center. The work is expected to commence during the fourth quarter of 2021 and be completed in the fourth quarter of 2024. In addition, the company has been awarded a contract valued at approximately $67M from the Port of Port Arthur to construct the Berth 6 Expansion Project in Port Arthur, Texas, that will allow for significant additional berthing capacity at the Port. The project is expected to commence in the fourth quarter of 2021 and be completed in the third quarter of 2024.

15:52 EDT CFTC orders Societe Generale to pay $1.5M for supervision failures - The Commodity Futures Trading Commission filed and settled charges against Societe Generale S.A., a provisionally registered swap dealer, for failing to comply with certain swap dealer requirements for disclosing mid-market marks to counterparties, reporting inaccurate swap valuation data to a swaps data repository, and related supervision failures. Reference Link

15:06 EDT General Motors unveils Ultifi software platform for new vehicle experiences - General Motors announced Ultifi, its end-to-end software platform designed to unlock new vehicle experiences and connect customers' digital lives. Ultifi will help enable the frequent and seamless delivery of software-defined features, apps and services to customers over the air, the company said. It offers the potential for more cloud-based services, faster software development and new opportunities to increase customer loyalty, GM added. Ultifi's functionality builds upon the Vehicle Intelligence Platform, GM's advanced electrical architecture. VIP-enabled vehicles today provide over-the-air capability, plenty of data bandwidth, robust cybersecurity and lightning fast processing power. On top of this foundation, GM engineers will separate key software into a new centralized layer that acts as a powerful hub for vehicle systems. The Ultifi platform will then enable accelerated development and deployment of software and applications over the air to millions of customers, without affecting basic hardware controls. "GM has decades of experience writing vehicle software, creating a solid foundation to build on," said Mark Reuss, GM president. "Now with Ultifi, we will be able to improve our software continuously, and deliver new features and apps to customers in a fraction of the time."

14:23 EDT Vocera awarded order from VA Department for Salisbury, NC medical center - Vocera was awarded a firm-fixed price delivery order from the Department of Veterans Affairs for the Medical Center in Salisbury, North Carolina to expand its existing Vocera solution "to enhance employee coverage throughout the facility," according to a post to the SAM.gov website with a contract award date of September 24 and original published date of September 29. Reference Link

13:58 EDT Boeing, U.S. Air Force extend C-17 sustainment partnership - Boeing will continue assuring the C-17 Globemaster III's worldwide mission readiness through a follow-on contract awarded by the U.S. Department of Defense, valued at up to $23.8B including potential options and incentives over ten years, the company said in a statement. The program is currently funded through September 2024 with a Phase I award of $3.5B, it added, noting that under the agreement, Boeing will continue performing critical sustainment activities, including engineering, field support, and material management, for the global fleet of 275 aircraft. The contract provides additional funding for new work scope such as international staffing to augment maintenance efforts and cyber security work statement.

13:54 EDT Google expands browsing feature for shopping with Lens, adds 'in stock' feature - Bill Ready, President of Commerce, Payments &NBU at Google (GOOG;GOOGL) said in part on Google's Keyword blog: "Shopping online is as much about inspiration and discovery as it is about the final purchase. ...We've made a number of changes over the last couple of years to improve your shopping experience, including giving you more choice when you shop on Google. For example, we've made it free for merchants to list on Google and made it easy for sellers on Shopify (SHOP) and other digital platforms to start selling on Google, so their products and inventory are discoverable for shoppers...And today, we're adding new tools to make it easier for shoppers to browse for inspiration, find new products and brands and ultimately find what they're looking for in a more visual way...Starting soon, iOS users will see a new button in the Google app to make all the images on a page searchable through Google Lens. Now, finding this lamp or that shirt (and ones like it) is just a tap away. We're also bringing Lens to Chrome on your desktop...Starting today, we're making it easier to browse for clothing, shoes and accessories on mobile right from your Search results. For example, when you search for "cropped jackets," we'll show you a visual feed of jackets in various colors and styles, alongside other helpful information like local shops, style guides and videos.Starting today, we're making it easier to browse for clothing, shoes and accessories on mobile right from your Search results. For example, when you search for "cropped jackets," we'll show you a visual feed of jackets in various colors and styles, alongside other helpful information like local shops, style guides and videos...You can now use the "in stock" filter to see only the nearby stores with a specific item on their shelves. Reference Link

13:48 EDT Electronic Arts announces expanded EA Sports FIFA 22 esports program - Electronic Arts and the Federation Internationale de Football Association, or FIFA, announced a new EA Sports FIFA 22 esports program "anticipated to attract tens of millions of players and viewers." EA said: "Featuring both 1v1 and 2v2 competitions, players will represent themselves, globally recognized esports organizations, real-world football clubs, and their nation in a diverse set of FIFA esports events. The three competitions featured in the expanded esports ecosystem are the FIFAe Club Series 2022, the FIFAe Nations Series 2022, and the EA Sports FIFA 22 Global Series on The Road to the FIFAe World Cup 2022. The three pinnacle events of the series will all take place in summer 2022."

13:31 EDT Mirum Pharmaceuticals up 7% following FDA approval of Livmarli - Shares of Mirum Pharmaceuticals are up $1.35, or 7%, to $20.10 after resuming trading.

13:22 EDT Eutelsat confirms receipt of proposal from Patrick Drahi, won't engage in talks - Eutelsat Communications confirms, pursuant to "market rumors," that Eutelsat that it has received an unsolicited, preliminary and non-binding proposal from Patrick Drahi in connection with a potential transaction on all of the company's share capital. "The relevant governance bodies of Eutelsat Communications have unanimously decided not to engage in discussions based on the terms of this proposal," the company said.

13:07 EDT Mirum Pharmaceuticals to resume trading at 1:30 pm ET - Shares of Mirum Pharmaceuticals are set to resume trading at 1:30 pm ET, with quotation to resume at 1:25 pm ET, according to Nasdaq. Shares were halted ahead of the company announcing news that the U.S. Food and Drug Administration has approved Livmarli oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome, or ALGS, one year of age and older.

13:00 EDT Fiserv to add about 2,000 jobs in New Jersey - Fiserv announced a commitment to continue and expand its presence in New Jersey. The company will add approximately 2,000 jobs to its existing presence and invest in a new location in Berkeley Heights, New Jersey, Fiserv said in a statement. The majority of the new jobs will be technology-related roles, and all will be based in a new Fiserv campus at The Park in Berkeley Heights, it added. "Fiserv has been in New Jersey for decades. Our new location in Berkeley Heights will be a dynamic hub of collaboration and innovation, bringing our people together in an inspiring workplace environment to create opportunity for unmatched energy and career growth experiences as we move payments and financial services forward on behalf of our clients," said Frank Bisignano, President and CEO of Fiserv.

12:50 EDT ViewRay announces FDA acceptance of new MRIdian features - ViewRay announced that it received acceptance from the Food and Drug Administration on its recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility.

12:16 EDT AT&T to require COVID-19 vaccination for CWA workers - AT&T said it is implementing a COVID-19 vaccination policy that extends its vaccine requirement to CWA-represented employees, helping to make its workplace safer for more of its employees and customers. This follows the policy the company announced in August, requiring most management employees to be vaccinated by Oct. 11, 2021. This new COVID-19 vaccination policy calls for CWA-represented employees who come into work locations, client and customer events or sites, or who are temporarily working from home to be fully vaccinated and compliant with the policy by Feb. 1, 2022, unless they get an approved job accommodation. Reference Link

12:06 EDT AlloVir treatment for virus-associated hemorrhagic cystitis gets orphan status - AlloVir's treatment for virus-associated hemorrhagic cystitis was granted orphan status by the FDA, according to a post to the agency's website. Reference Link

12:01 EDT MoneyLion falls -13.1% - MoneyLion is down -13.1%, or -$1.06 to $7.03.

12:00 EDT Li-Cycle rises 7.8% - Li-Cycle is up 7.8%, or 86c to $11.86.

12:00 EDT Elevate Credit rises 11.1% - Elevate Credit is up 11.1%, or 39c to $3.91.

11:47 EDT Disney says 'Star Wars: Boba Fett' series streaming on Disney+ December 29 - Disney announced that upcoming original series "Star Wars: The Book of Boba Fett" will start streaming exclusively on Disney+ December 29. Reference Link

11:09 EDT Exxon Mobil, Rosneft announce MOU to cooperate in carbon management - ExxonMobil (XOM) and Rosneft (RNFTF) announce that they have signed a Memorandum of Understanding, or MOU, to cooperate on the assessment of lower-carbon technologies to reduce greenhouse gas emissions from their operations. "The companies will consider the prospects of new projects initially focused on carbon capture and storage and the development of lower-carbon fuels, such as hydrogen and ammonia. The MOU continues the cooperation between the two companies and signals their intent to jointly develop and implement lower-carbon projects, as well as exchange their respective experience and technological solutions in promising areas," they stated. Reference Link

11:01 EDT Vuzix signs distribution agreement with Acuraflow, receives initial order - Vuzix announced that it has signed a distribution agreement with Acuraflow, a developer and deployer of sustainable management solutions, and has received an initial order from them for Smart Glasses. "This distribution agreement with Vuzix is very important for us to continue serving LATAM with digital transformation in industrial companies and to expand into education and healthcare. We view Vuzix products as best in class, especially for logistics, picking and medical use cases, where Vuzix excels on being lightweight and easy to use. As a master distributor in the region, our customers will be able to purchase Vuzix products with better shipping conditions, competitive landed costs, and a host of value-added services," stated Lucas Reed, Business Development Manager at Acuraflow.

10:53 EDT Generac drops 5.5% to $402.35 after providing 3-year targets at Investor Day

10:48 EDT Generac sees $2B-$2.5B of free cash flow for 2022-2024

10:16 EDT Check Point, Alkira collaborate to bring security to cloud workloads - Alkira and Check Point Software Technologies announced a technology alliance to provide Check Point Software's CloudGuard firewalls in Alkira's Cloud Network infrastructure as-a-Service, or CNaaS. "This comes as organizations deploying application workloads to the cloud are struggling with the complexity of implementing consistent enterprise-wide security controls spanning cloud, multi-cloud and on-premises environments," the company said. The Check Point CloudGuard platform provides cloud native security with threat prevention for all assets and workloads enabling customers to deploy the same security in the cloud that they are used to with on-premises systems. Alkira Cloud Services Exchange fully automates the provisioning, licensing, service insertion, scaling and health monitoring of CloudGuard network security gateways. Once CloudGuard has been provisioned within an Alkira CXP it can provide: security policy to and between public clouds; cloud hosted, stateful firewall services for branches and data centers; regionalized Internet breakouts for secure SaaS application access; cloud DMZ environment for Internet facing applications; and shared cloud application services for partners and M&As.

10:08 EDT Cousins Properties announces lease with Visa in Atlanta - Cousins Properties (CUZ) announced that Visa (V) has signed a long-term, approximately 123,000 square foot lease at 1200 Peachtree in Midtown Atlanta. Visa is expected to create approximately 1,000 new jobs in the region over the next several years as it establishes a permanent office presence in the Atlanta market. Initial occupancy is expected during the fourth quarter of 2022.

10:01 EDT QuickLogic signs worldwide distribution agreement with Digi-Key Electronics - QuickLogic announced it has signed a worldwide distribution agreement with Digi-Key Electronics. The company's EOS S3 low power microcontrollers, supported by 100% open-source software is now available at Digi-Key Electronics.

10:00 EDT Galileo Acquisition Corp. falls -9.4% - Galileo Acquisition Corp. is down -9.4%, or -$1.00 to $9.64.

10:00 EDT KE Holdings rises 5.4% - KE Holdings is up 5.4%, or 94c to $18.42.

10:00 EDT Regis rises 9.7% - Regis is up 9.7%, or 40c to $4.50.

09:47 EDT IronNet falls -5.5% - IronNet is down -5.5%, or -$1.45 to $24.91.

09:47 EDT Spirit AeroSystems rises 4.8% - Spirit AeroSystems is up 4.8%, or $2.07 to $45.23.

09:47 EDT Worthington rises 7.1% - Worthington is up 7.1%, or $3.96 to $59.65.

09:28 EDT Lightspeed drops 6% to $106.05 following Spruce Point short report

09:27 EDT Editas Medicine off lows following report of data on EDIT-101 - Editas Medicine shares, which had been down by a double-digit percentage immediately following the announcement of initial clinical data from the ongoing Phase 1/2 BRILLIANCE clinical trial of EDIT-101 for the treatment of blindness due to Leber congenital amaurosis 10, have come off their lows to be down about 5% to $49.69 ahead of the open.

09:18 EDT Surna announces benching, racking line-up - Surna announced another expansion to its products and service offering to include benching and racking equipment. Surna is a seasoned leader in the controlled environment agriculture market and is intent on bringing the most efficient and sustainable designs and systems to the industry. Surna's benching and racking can be adapted to the grower's specific requirements. Surna now offers a full portfolio of benching and racking options that include single-tier, ebb and flow growing benches, stationary benches, rolling and tracking benches, multi-tier vertical farming racks, and cloning and drying racks.

09:16 EDT Electric Last Mile Solutions ships first Urban Delivery EVs to customers - Electric Last Mile Solutions announced that it has shipped its first Urban Delivery units to customers, marking the launch of the first commercial Class 1 EV in the U.S. market. The Urban Delivery EVs came out of ELMS' production facility in Mishawaka, Indiana and were shipped to Randy Marion Automotive Group, one of the country's largest commercial dealerships, as part of a binding purchase order for 1,000 units that was announced last week.

09:11 EDT Stifel Financial to acquire Vining Sparks - Stifel Financial announced it has entered into a definitive agreement to acquire 100% of Vining Sparks and its affiliates. Terms of the transaction, which is expected to close in the fourth quarter of 2021, were not disclosed. Vining Sparks has approximately 275 employees in 13 offices throughout the United States. The firm provides institutional fixed income brokerage, balance sheet management and underwriting services to more than 4,000 institutional clients in all 50 states. "This transaction brings together two similar client-centric institutional fixed income businesses based on a philosophy of providing value-added services supported by strategy, analytics and technology," said Ronald Kruszewski, Chairman and CEO of Stifel. "The cultural and strategic fits between our firms are substantial, as Vining's core depository client base had less than 5% net revenue overlap with Stifel's fixed income client base last year. Ultimately, we see opportunity to leverage Vining's core relationships across both the Stifel and Keefe, Bruyette and Woods platforms to further our position as the market leader, and most trusted advisor, in the financial services sector. I am also happy to welcome Mark Medford who will be joining us as a Vice Chairman of Stifel Financial."

09:10 EDT Ferroglobe announces plans to restart silicone metal facility in US - Ferroglobe announces that its subsidiary, Globe Metallurgical, is considering plans to restart its silicon metal facility in Selma, Alabama. GMI is working with state and local representatives and is seeking New Market Tax Credits for the project, which would help offset commissioning costs and enable the company to acquire and upgrade equipment to begin production of silicon metal. Combined, the two-furnace operation has total annual capacity of 22,000 tons of silicon metal. GMI would plan on restarting one furnace in December 2021 and hopes to restart the second furnace by March 2022. Combined the facility would require approximately 100 local new hires, and 150 indirect local suppliers. Marco Levi, Ferroglobe's Chief Executive Officer commented, "Ferroglobe is one of the few silicon metal producers with meaningful idled capacity which can be restarted globally. In light of favorable market conditions in North America heading into 2022, the Selma facility will be an important asset in our U.S. silicon platform going forward, particularly with the permanent shut down of our Niagara Falls, New York facility as part of our strategic turnaround plan. The restart of the Selma facility has been a part of our multi-year strategy, and we feel this is an opportune time to commence the process."

09:08 EDT Verisk Analytics enters collaboration with Insurance Regulatory Consultants - Insurers looking to enhance their operations, develop custom products and comply with state regulations can now benefit from a new collaboration between Verisk and Insurance Regulatory Consultants, a full-service state filing and regulatory compliance company. As part of the collaboration, Verisk can leverage the deep domain expertise and robust data of its ISO business to help new and existing insurers launch new products, improve their actuarial analysis and enhance their strategic decision making. IRC can assist the insurers in the development of these new products and guide them through the regulatory approval process.

09:07 EDT Editas Medicine announces initial clinical data from Phase 1/2 BRILLIANCE trial - Editas Medicine announced initial clinical data from the ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101. EDIT-101 is under development for the treatment of blindness due to Leber congenital amaurosis 10, a CEP290-related retinal degenerative disorder. The data, including preliminary patient safety and efficacy assessments relating to potential clinical benefits, are being presented today in an oral presentation at the XIXth International Symposium on Retinal Degeneration by Dr. Mark Pennesi, M.D., Ph.D. Preliminary results include safety and efficacy data from the first two cohorts, the adult low-dose cohort and the adult mid-dose cohort. The BCVA eligibility criteria for the adult low-dose cohort are light perception, black-white discrimination, and white field projection. For the adult mid-dose and all other cohorts, the first subject is required to have light perception to BCVA of 1.6 logMAR. BCVA criteria for all subsequent subjects is LP to 0.4 logMAR. Safety data was reported with respect to all six subjects treated in the low dose and mid-dose cohorts. Most adverse events were mild and primarily resulting from the surgical procedure and subretinal injection. There were no dose limiting toxicities defined as a vision-threatening toxicity or severe non-ocular AE that occurs before or at the Week 4 visit and is assessed by the investigator as being related to EDIT-101 and not the administration procedure. Mild anterior chamber inflammation was observed, and adequately controlled with oral steroids. No Cas9-specific antibody or T-cell response was detected. To date, no treatment-related cataracts, edema, or retinal thinning have been observed. Efficacy was assessed based on available data from five subjects treated in the adult low-dose cohort and the adult mid-dose cohort, who had at least three months of post treatment follow-up, focusing on those measures demonstrated to be consistent and reproducible in subjects with CEP290 retinal degeneration, including: BCVA, FST, and Visual Function Navigation. Two of three subjects in the mid-dose cohort followed for up to six months showed efficacy signals suggesting productive editing and providing initial support for clinical benefits, including improvements in BCVA, FST, and/or mobility navigation. BCVA is assessed by using the Early Treatment of Diabetic Retinopathy Study eye chart, or the Berkeley Rudimentary Vision Test, or the Lea Symbols 15-line pediatric eye chart. FST measures the sensitivity of the entire visual field by testing for the lowest luminance flash which provokes a visual sensation. Patients are presented with blue, red, and white stimuli, and based on the blue-red difference, the experimenter can determine the sensitivity of rod-mediated and cone-mediated perceptions. Navigational capabilities were assessed using standardized mobility testing with four different navigation courses, designed with varying levels of difficulty. Mid-dose cohort Subject 1 showed improvement in BCVA of approximately 0.7 logMAR at Month 1.5 which was sustained at Month 6 follow-up. In addition, there was a positive trend toward improved retinal sensitivity by FST in the study eye relative to the untreated eye. The subject also demonstrated a 5-level improvement in mobility at Month 6, as assessed with the VNC. Mid-dose cohort Subject 2 showed improvement by Month 3 with a stable BCVA and a notable improvement in retinal sensitivity in the study eye relative to the untreated eye by FST, detectable at Month 1.5 that continued to improve through Month 3. In June, the Independent Data Monitoring Committee endorsed proceeding with the first pediatric cohort based on a review of clinical safety data from the adult low-dose and adult mid-dose cohorts. Treatment in the adult high-dose cohort continues and the pediatric mid-dose cohort is commencing.

09:06 EDT Bank of Nova Scotia partners with Google Cloud - Scotiabank (BNS) and Google (GOOG) Cloud announced a strategic partnership to accelerate its global data and analytics strategy. By moving its customer data onto Google Cloud and leveraging its data analytics and AI solutions, Scotiabank aims to be able to: leverage data for predictive offers; improve customer interactions through AI; and unify data silos across the organization.

09:06 EDT J&J's Janssen announces start of Phase 3 trial of RSV vaccine in older adults - The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen's investigational adult vaccine against lower respiratory tract disease caused by respiratory syncytial virus, or RSV, when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere. "Positive data from our first RSV vaccine efficacy study and the initiation of the Phase 3 EVERGREEN study are crucial milestones in the clinical development of our investigational RSV adult vaccine, which has the potential to safely and effectively prevent lower respiratory tract disease caused by RSV in older adults. With no vaccine or broadly-indicated antiviral treatment available, preventive solutions to address the significant morbidity and mortality in older adults caused by RSV have long been an unmet need," said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development.

09:04 EDT China Liberal Education awarded utility model, appearance design patents - China Liberal Education announced that its self-developed all-in-one teaching machine, AI-Space, was granted a utility model patent and an appearance design patent by the China State Intellectual Property Administration. The name of the utility model is multimedia integrated device, and the utility model patent certificate was obtained on September 24 (Patent Number: ZL 2021 2 0084718.9). The appearance design patent certificate was obtained on April 23 (Patent Number: ZL 2020 3 0730801.X).

09:03 EDT Lowe's offering 10% discount for first responders for three days - Lowe's will offer a new 10% discount coupon for eligible first responders in Lowe's stores nationwide and on Lowes.com Oct. 22 through Oct. 24, in recognition and appreciation for their service. Firefighters, emergency medical technicians/paramedics, police officers, 911 dispatchers, nurses and physicians nationwide can register for the coupon through Oct. 24 for this special offer by visiting Lowes.com/firstresponders. Throughout Fire Safety Month this October, Lowe's will also continue its tradition of raising public awareness. On Oct. 2 and Oct. 9, more than 1,000 Lowe's stores nationwide will host fire safety education events and demos in Lowe's parking lots led by local fire departments with fire trucks and First Alert.

09:02 EDT Hepion Pharmaceuticals announces results from DDI study with CRV431 - Hepion Pharmaceuticals announced results from a Drug-Drug Interaction, or DDI, study with its lead drug candidate, CRV431. The randomized, open label DDI study was conducted in healthy volunteers to determine if single or multiple oral doses of ketoconazole influence the pharmacokinetics of CRV431 and its major metabolites. The study also examined if single or multiple once daily oral doses of CRV431 effected the PK of midazolam and its metabolite, 1-hydroxymethyl midazolam. Additionally, the safety and tolerability of CRV431 when administered concomitantly with either ketoconazole or midazolam was assessed. Each study subject participated in both parts of the two-staged trial. As expected, following five daily oral doses of ketoconazole, the maximum blood concentration of CRV431 increased approximately five-fold, while the exposure, as measured by the area-under-the-curve from time of dosing to 24 hours, increased almost four-fold. When CRV431 was dosed with midazolam, the exposures of midazolam and 1-hydroxymethyl midazolam were not significantly altered. However, both the Cmax and AUC0-24 of CRV431 were increased by approximately two-fold. Todd Hobbs, MD, Hepion's Chief Medical Officer added, "Patients diagnosed with fatty liver disease and/or NASH are commonly prescribed multiple life-long drug therapies to manage associated medical conditions, such as diabetes and hypertension. And typically, the number of medications prescribed to NASH patients increases with increasing severity of disease, such that those with advanced fibrosis and cirrhosis are at greatest risk for drug interactions as a result of polypharmacy. In fact, a study characterizing polypharmacy determined that NASH patients received, on average, seven medications and patients with cirrhosis received an average of 11 medications. It is, therefore, vitally important to fully understand how the disposition of CRV431 may potentially be altered by other drugs or how CRV431 might alter the PK and performance of co-administered drugs. This knowledge will not only be valuable when designing our future clinical trials but could also ultimately help guide the use of CRV431 in a commercial setting."

08:45 EDT Heico acquires 80.1% of RH laboratories, sees accretion - Heico announced that its Electronic Technologies Group acquired 80.1% of the stock of RH Laboratories for cash paid at closing. RH's founders will continue to own the balance of the company. Further terms and financial details were not disclosed. Heico stated that it expects the acquisition to be accretive to its earnings within the first year following the closing. RH was founded in 2001 by Benjamin Robinson, his son Stephen Robinson and Frank Holt. All three will continue in their pre-closing roles, with Benjamin remaining as CEO, Stephen remaining as president and Frank continuing as VP of engineering. Further, the Robinsons and Holt will continue to own 19.9% of RH. Heico stated that it does not expect any employee turnover to result from the acquisition.

08:44 EDT Quanta's Medolife Rx files bi-annual report with MOE of the Dominican Republic - Medolife Rx, which is a majority owned subsidiary of Quanta, announced that it has completed a bi-annual filing with the Ministry of Environment of the Dominican Republic, which detailed the expansion of its scorpion reservation and exceeded the expectations of the regulatory body. The MOE expressed further interest in the Company's flagship product, Escozin, which has recently renewed its registration in the DR as a natural alternative medicine for oncological treatments.The bi-annual filing is a requirement of the agreement between the MOE and Medolife. It is intended to communicate updates at the reservation, progress on its build out, observations of studies conducted by the Company, and outlines next steps Medolife will take in its development of the first-of-its-kind reservations in the Neyba and Azua provinces. The Azua region was selected for development as it closely resembles the natural environment of the Rhopalurus princeps species of scorpion. Peptides found in the scorpions are used in many of Medolife's pharmaceutical and nutraceutical product lines, and the reservation allows for the cultivation and extraction of the peptides in a safe and humane way. The reservation serves as the Company's supply pipeline of these peptides, which is known to be one of the most expensive liquids in the world, allowing the Company to produce peptide-based products at a fraction of the cost should it seek supply elsewhere. Especially noteworthy in the filing are details on the build out of the reservation, where the Company has expanded the original space by sixfold. Construction of the laboratory is still underway and the Company plans to continue to develop the land in a way that positively affects the quality of the scorpions. In addition to surpassing the expectations from the MOE, the Company also received interest from the MOE in purchasing Escozine, Medolife's lead drug candidate. The report included clinical observations made by the Company on the potential therapeutic and palliative properties of Escozine in patients who have tested positive for the SARS-CoV-2 virus, and preventative properties in hospital staff that reported zero new infections over the course of the clinical observation. The MOE is interested in purchasing Escozine as a preventative alternative medicine for its employees.

08:43 EDT Nemaura Medical launches beta version of its metabolic health program - Nemaura Medical announces the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application. MiBoKo addresses a "significant mass market opportunity" that the company believes could benefit roughly a third to half of the population by using a noninvasive glucose sensor to measure and monitor a user's metabolic health score, which is based on glucose tolerance or insulin resistance. Those with prediabetes or obesity concerns, or even those looking to maintain better health through more careful glucose control, could benefit from such a metabolic health program. MiBoKo's next-level health tracking program uses a small sensor and a mobile app to provide users with personalized information by tracking their metabolism. A user can find out how their body responds to sugar through their metabolic health score - and how what they eat and what they do every day uniquely affects their metabolic health. CEO Faz Chowdhury explained, "With MiBoKo, we are able to extend our proprietary noninvasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health. At Nemaura, we continue to look for the intersection of patient comfort and convenience through advanced and unique technology that addresses significant healthcare needs for large patient populations. We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market."

08:42 EDT Limoneira announces $10M share repurchase program - Limoneira announced that the Company's Board of Directors authorized the repurchase of up to $10M of the Company's issued and outstanding common stock. Harold Edwards, President and Chief Executive Officer of the Company, stated, "The Board's decision to authorize this share repurchase program is a clear indication that they, along with our management team, believe Limoneira is positioned for continued long-term growth through both our strategic assets and our consistent global supply of fresh fruit. Our Company remains committed to the disciplined, opportunistic deployment of capital in order to maximize value for our shareholders."

08:41 EDT Limoneira announces $10M share repurchase program - Limoneira announced that the Company's Board of Directors authorized the repurchase of up to $10M of the Company's issued and outstanding common stock. Harold Edwards, President and Chief Executive Officer of the Company, stated, "The Board's decision to authorize this share repurchase program is a clear indication that they, along with our management team, believe Limoneira is positioned for continued long-term growth through both our strategic assets and our consistent global supply of fresh fruit. Our Company remains committed to the disciplined, opportunistic deployment of capital in order to maximize value for our shareholders."

08:40 EDT Scopus BioPharma's Duet Therapeutic to present preclinical data - Scopus BioPharma announced the release of preclinical data being presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society. Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics and President - Immuno-Oncology of Scopus, is presenting data in talks entitled: Bispecific Oligonucleotide Targeting TLR9 and STAT3 Signaling for B Cell Lymphoma Immunotherapy; Bifunctional Oligonucleotides for Systemic Treatment of Immunologically Cold Solid Tumors. Duet Therapeutics is a wholly-owned subsidiary of Scopus. Data from two different studies benchmarked Duet's proprietary bifunctional oligonucleotides, CpG-STAT3siRNA and CpG-STAT3ASO, against Checkpoint Inhibitors in lymphoma and prostate tumor models in mice. Dr. Horsager is presenting results of a study comparing Duet's clinical-stage, siRNA-based molecule, or DUET-01, to Checkpoint Inhibitors in an A20 mouse model of B-cell lymphoma. PD-1 and CTLA-4 Checkpoint Inhibitors had limited efficacy while intratumoral administration of DUET-01 resulted in complete lymphoma regression. Dr. Horsager is also presenting results of a study comparing Duet's antisense-based bifunctional molecule, or DUET-02, to both PD-1 and CTLA-4 Checkpoint Inhibitors in a bone localized tumor model of metastatic prostate cancer. Clinical observations have indicated that these prostate tumors are resistant to Checkpoint Inhibitors. By comparison, data collected in the laboratory of Marcin Kortylewski, Ph.D., Duet's Senior Scientific Advisor, DUET-02 monotherapy induced potent antitumor immune responses and resulted in long-term animal survival. Overall, the studies indicate that Duet's bifunctional oligonucleotides can expand the reach and efficacy of cancer immunotherapies beyond the current standard-of-care treatments.

08:38 EDT Beyond Meat launches Beyond Breakfast Sausage Links in Canada nationwide - Beyond Meat is shaking up the breakfast game in Canada by launching plant-based Beyond Breakfast Sausage Links in grocery stores nationwide, marking Beyond Meat's entry into the Canadian retail breakfast category. Consumers can find the savoury plant-based sausage links at all major retailers across Canada. Beyond Breakfast Sausage Links are crafted to deliver the craveable flavor and juicy texture of traditional breakfast sausage, while offering 12g of protein per serving and 35% less sodium than the leading brand of pork sausage. Beyond Breakfast Sausage Links are made of simple, plant-based ingredients like peas and rice, with no GMOs, soy, gluten, antibiotics, hormones or cholesterol.

08:36 EDT North American Construction announces amended, extended credit facility - North American Construction announced it has finalized an amendment and extension of its senior secured credit facility. The facility maturity date has been extended by one year with a new maturity date of October 8, 2024. In addition to the extension of existing favourable terms, amendments have also been incorporated that provide the Company greater flexibility in operating through joint ventures, including joint ventures related to larger contracts under public-private-partnership financing models. The Credit Facility maintains NACG's borrowing capacity of $325 million with an ability to increase maximum borrowings by an additional $50 million, subject to certain customary conditions. The existing allowance for equipment financing of up to $150 million over and above the facility limit will continue, providing supplemental borrowing flexibility. The Credit Facility remains comprised solely of a revolver with no scheduled repayments and is not governed by a borrowing base that limits available borrowings. Financial covenants are consistent with the previous agreement and are tested quarterly on a trailing four quarter basis.

08:36 EDT Transcontinental announces renewal of NCIB plan - Transcontinental Inc. has been authorized to purchase for cancellation on the open market, between October 1st, 2021 and September 30, 2022, up to 1,000,000 of its Class A Subordinate Voting Shares and up to 190,300 of its Class B Shares, representing approximately 1.37% of the 73,111,944 issued and outstanding Class A Subordinate Voting Shares and of the 13,913,226 issued and outstanding Class B Shares as of September 17, 2021. The average daily trading volume on the Toronto Stock Exchange of Class A Subordinate Voting Shares for the past six months was 175,745 and the average daily trading volume on the Toronto Stock Exchange of Class B Shares for the past six months was 392. In accordance with the Toronto Stock Exchange requirements, a maximum daily purchase of the greater of 25% of these averages or 1,000 shares may be made, which represent a total of 43,936 Class A subordinate Voting Shares and a total of 1,000 Class B Shares. The purchases will be made in the normal course of business at market prices through the facilities of the Toronto Stock Exchange and/or alternative Canadian trading systems in accordance with the requirements of the exchange, and/or subject to the approval of any securities authority by private agreements. If applicable, purchases through private agreements will be executed at a price that is less than the prevailing market price on the Toronto Stock Exchange at the time of the purchase. The Corporation believes that the purchase of the Class A subordinate Voting Shares and Class B Shares would constitute an appropriate and desirable use of its funds to increase long-term shareholder value. The last normal course issuer bid, in effect from October 1st, 2020 until September 30, 2021, covered a maximum of 1,000,000 Class A Subordinate Voting Shares and 191 320 Class B Shares. At the close of the market on September 27, 2021, Transcontinental Inc. did not purchase Class A Subordinate Voting Shares or Class B Shares. In connection with the program, the Corporation established an automatic securities purchase plan to provide standard instructions regarding how the Corporation's shares are to be repurchased under the program. Accordingly, the Corporation may repurchase its shares under the automatic plan on any trading day during the program including during self-imposed trading blackout periods. The automatic plan will commence and should terminate together with the program. It constitutes an "automatic plan" for purposes of applicable Canadian securities legislation and has been reviewed by the Toronto Stock Exchange.

08:32 EDT Churchill Downs to sell Arlington Heights property to Chicago Bears for $197M - Churchill Downs announced that the company has signed a Purchase and Sale Agreement with the Chicago Bears. The company has agreed to sell the 326-acre property in Arlington Heights, Illinois, currently the home of Arlington International Racecourse, for $197.2M. The closing of the sale of the Property is subject to the satisfaction of various closing conditions. The company anticipates closing the sale of the Property in late 2022 / early 2023. CDI is planning to use the proceeds of the sale to purchase or invest in replacement property that qualifies as an Internal Revenue Code Section1031 transaction.

08:23 EDT Hill to provide supervision services for Kosovo's upgrade of Rail Route 10 - Hill International announced it was awarded a contract by Kosovo Railways to provide supervision services for Phase 2 of the rehabilitation and upgrade of Rail Route 10. Rail Route 10 connects Kosovo's railway network with the regional and pan-European network and was last overhauled 40 years ago. Phase 1 of the Route 10 project, which Hill also supports, involves a span connecting Fushe Kosove, just outside of Pristina in central Kosovo, with North Macedonia. Phase 2 involves rehabilitating and upgrading a 34.4 km segment of the route from Fushe Kosove north to Mitrovice. These efforts aim to secure the long-term future of the line while increasing traffic safety and enabling a higher operating speed. Work at Fushe Kosove station includes passenger facilities, a freight station, maintenance workshops, and a locomotive depot. As part of an international consortium, Hill will provide construction management technical and financial supervision of the works for the project in accordance with the FIDIC Conditions of Contract and relevant national legislation.

08:22 EDT Porch Group's Homeowners of America expands into Utah - Homeowners of America, a property and casualty insurance provider and subsidiary of Porch Group, announced the launch of service in Utah. Porch completed its acquisition of HOA in April 2021. The company is seeking to drive growth in the states currently offering services and continue the national expansion effort. With the addition of Utah, HOA now operates in nine states. "We're continuing the execution of our national expansion plan with the introduction of the HOA insurance offerings to Utah," said Matt Ehrlichman, Porch founder, chairman, and CEO. "Through our early access to homeowners, we remain well-equipped to support them at every stage of homeownership, including insurance product offerings."

08:21 EDT Kolab Project launches 132 Series Live Resin Soft Chews - Kolab Project announces the launch of 132 Series Live Resin Black Cherry Punch Soft Chews, Canada's first cannabis-infused live resin edible. Kolab Project 132 Series Live Resin Black Cherry Punch Soft Chews are for cannabis enthusiasts who love the true-to-plant taste of cannabis, and are an extension of Kolab Project's true-to-strain product line-up that includes the 232 Series Live Terpene vape cartridges and 232 Series Diamonds concentrates. Kolab Project 132 Series Live Resin Black Cherry Punch Soft Chews are available now for purchase on OCS.ca and in retail outlets in Ontario, Alberta, Saskatchewan, and Manitoba, with additional provinces expected to launch in coming months. Kolab Project is a cannabis brand owned and operated by Auxly Cannabis Group.

08:19 EDT Bionano Genomics announces publication of research data evaluating OGM for FSHD - Bionano Genomics announced the publication of the largest clinical research study to date evaluating optical genome mapping, or OGM, for facioscapulohumeral muscular dystrophy, or FSHD, which concluded that OGM can be performed more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. This study describes how OGM can be adopted as an alternative to Southern blot analysis for the identification of chromosomal abnormalities associated with FSHD, a neuromuscular disorder resulting in progressive weakness and atrophy of muscles. In this study of 351 participants, the authors Stence et al., validated the use of OGM with Bionano's Saphyr system to determine the size and haplotype of D4Z4 alleles to confirm a diagnosis of FSHD. The study's authors found that OGM had much higher sizing accuracy and was greater than99% concordant with Southern blot analysis. "The study completed by Dr. Stence and team demonstrated the superior performance of OGM over traditional molecular genetic testing for FSHD," commented Erik Holmlin, PhD, CEO of Bionano Genomics. "As the largest OGM clinical study to date, the study demonstrated that using the Saphyr system to perform FSHD analysis resulted in a significantly faster turnaround time, as the OGM turnaround time was only 5 days as compared to Southern blot at 11 days. The ability to obtain accurate, reliable data more quickly allowed for the timely application of this information for the management of study participants. We believe that studies like this one could pave the way for broad adoption of OGM for a wide variety of applications in genetic disorders and cancer."

08:17 EDT Allena Pharmaceuticals commences dosing in second Phase 2a trial of ALLN-346 - Allena Pharmaceuticals reported that it has dosed the first patient in a second Phase 2a trial of ALLN-346, a novel, orally-administered, urate-degrading enzyme in development for the treatment of gout in patients with chronic kidney disease. The Phase 2a program, comprised of this two-week outpatient trial and a one-week inpatient trial currently being conducted in a clinical pharmacology unit, is designed to assess initial bioactivity data and additional safety data for ALLN-346, the second orally delivered, non-absorbed enzyme developed using Allena's proprietary oral enzyme technology platform. "We are pleased to initiate our second trial in the Phase 2a program for ALLN-346," noted Louis Brenner, M.D., President and Chief Executive Officer of Allena. "We look forward to reporting initial data from this study, as well as initial data from our ongoing seven-day inpatient study in subjects with hyperuricemia, beginning in late 2021 or early 2022. As we evaluate the initial data from the Phase 2a program, we will potentially study additional patients to assist us in determining the optimal dosing paradigm and target population for later stage clinical trials."

08:16 EDT Syros reports 1st patient in dose confirmation study of ATO oral for APL - Syros Pharmaceuticals announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide, ATO. The trial will evaluate the pharmacokinetics , safety, and tolerability of SY-2101 to confirm the optimal dose to advance into a planned Phase 3 clinical trial in newly diagnosed acute promyelocytic leukemia patients. "The current standard of care cures most patients but is tremendously burdensome, requiring regular and lengthy infusions of an IV formulation of ATO over nearly a yearlong course of treatment," said Farhad Ravandi, M.D., Professor of Medicine, Chief of Section of Acute Myeloid Leukemia, Department of Leukemia at The University of Texas - MD Anderson Cancer Center. "An oral form of ATO that offers similar efficacy while dramatically reducing the treatment burden would represent a major advance for APL patients. The preliminary Phase 1 data for SY-2101 are very promising, and I look forward to its continued advancement in the current and future studies." "We are thrilled to now be dosing patients in our dose confirmation study of SY-2101," said David A. Roth, M.D., Chief Medical Officer at Syros. "This milestone represents an important step toward delivering a new option for people with APL and a meaningful advance in our efforts to build a leading portfolio of targeted hematology therapies. We believe SY-2101 could quickly become the new standard of care for APL by offering patients similar efficacy with a substantially more accessible and convenient therapy. We plan to move swiftly from our dose confirmation study into a Phase 3 trial next year, with the goal of filing a New Drug Application, NDA, in 2024." ...Syros expects to report data from this study in the first half of 2022. Based on the results of the dose confirmation study, Syros expects to initiate a Phase 3 clinical trial in newly diagnosed APL patients. Based on input from the FDA, Syros believes molecular complete response rate and event-free survival in comparison to historical control data with IV ATO may support accelerated and full approval, respectively.

08:15 EDT electroCore announce manuscript from SAVIOR-1 study of nVNS in COVID-19 patients - electroCore announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation, nVNS, using gammaCore Sapphire in patients admitted to the hospital for treatment of COVID-19; is available on MedRxiv and has been submitted for peer review. This study was an investigator-initiated trial conducted at the Hospital Clinico Universitario de Valencia, Spain. The SAVIOR-1 study enrolled 110 patients over 18 years of age between April 2020 and February 2021. A total of 97 patients comprised of 47 treatment subjects and 50 control subjects provided baseline demographic and medical history data. The study was designed to evaluate the safety and feasibility of nVNS when administered in addition to the then-standard of care in patients hospitalized with active SARS-CoV-2 infection compared with standard of care alone. The analyses identified significant treatment differences for certain biomarkers of inflammation. Decreases from baseline in C-reaction protein levels were significantly greater for the nVNS treatment group as compared to the control group throughout the five-day period combined and on day 5 compared to the day 1 baseline period alone. At day 1, CRP levels were highly elevated for 90% of all subjects, but by days 3 and 5, the percentage of subjects with normal CRP levels improved markedly in the nVNS group with day 3 CRP levels at 17.9% vs. 52.2% in the control. Additionally, the nVNS group had a significantly greater decrease from baseline in procalcitonin level at day 5 as compared to the control group. Increased levels of CRP, procalcitonin and d-dimer have all been reported to be associated with more severe disease and the lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients' COVID-19 symptoms. nVNS was well tolerated with no major device related adverse events and the therapy was administered three times daily on most patients as outlined in the study protocol.

08:14 EDT Cidara Therapeutics to present new Rezafungin data at TIMM Congress - Cidara Therapeutics announced that it will present new clinical and non-clinical data in two poster presentations at the 10th Congress on Trends in Medical Mycology taking place in-person in Aberdeen, Scotland and virtually from October 8-11, 2021. Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections, including in critically ill patients. Cidara expects to announce top-line data from its Phase 3 ReSTORE trial by the end of 2021 and anticipates filing a New Drug Application in the U.S. and similar regulatory filings outside the U.S. in mid-2022.

08:11 EDT Veeva partners with LEO Pharma for paperless digital trials - Veeva and LEO Pharma, a company specializing in medical dermatology, announced a strategic technology partnership to enable scalable digital trials that are patient-centric and paperless. Building on its success with the Veeva Clinical Operations Suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help to shape the Veeva digital trials roadmap. LEO Pharma will utilize the integrated suite of Veeva clinical products.

08:10 EDT Kratos Defense receives $50M single award, sole source IDIQ contract - Kratos Defense & Security Solutions announced that its Kratos Unmanned Aerial Systems division has recently received an approximate $50 million, single award, sole source, high performance jet drone system related Indefinite Delivery, Indefinite Quantity (IDIQ) contract from a United States Government Agency. KUAS is the industry leader in the rapid design, manufacture and delivery of affordable, high performance jet drone systems. Work under this contract award will be performed as funded task orders are issued by the customer at secure Kratos facilities and customer locations. Due to customer related, competitive, security, and other considerations, no additional information will be provided.

08:09 EDT Star Peak Corp II stockholders approve Benson Hill combination - Star Peak Corp II announced its stockholders have voted to approve the business combination with Benson Hill, a food technology company, as well as other proposals presented at Star Peak's special meeting of stockholders held on September 28.

08:09 EDT Asensus says Japan's Sapporo Medical University to use Senhance Robotic Surgery - Asensus Surgical today announced Sapporo Medical University Hospital, located in Hokkaido, Japan, has entered into an agreement to lease and utilize a Senhance Surgical System. "The Department of Surgery, Surgical Oncology and Science at Sapporo Medical University Hospital is an outstanding institution which is well known for utilizing the most advanced surgical technologies, and we are very excited to partner with them to expand their existing surgical robotics program," said Anthony Fernando, Asensus Surgical President and CEO. "Japan remains a focus market for Senhance. With a dedicated training center and a growing number of active systems at prestigious institutions, we expect to further accelerate adoption in the region in the future.''

08:08 EDT Farmmi to acquire Xiangbo for RMB 70M - CEO Yefang Zhang said, "We have agreed to acquire all the shares of Xiangbo for approximately RMB 70 million based on our decision to expand Farmmi's forest related business. Xiangbo's subsidiary, Yudu County Yada Forestry Co., Ltd. owns 1,4438.5 mu of economic forest in Yudu County, Ganzhou City, Jiangxi Province. Xiangbo primarily uses its acreage in the cultivation and production of Moso Bamboo, Camellia Oleifera and Chinese Fir trees."

08:07 EDT Humanigen announces LIVE-AIR study achieved primary endpoint - Humanigen announced a presentation of the results from the company's randomized, double-blind, placebo-controlled LIVE-AIR Phase 3 study at IDWeek 2021 taking place virtually from September 29 to October 3. The LIVE-AIR study achieved its primary endpoint of survival without ventilation measured through day 28 following treatment. Survival without ventilation is an important clinical endpoint that measures not only mortality, but the morbidity associated with mechanical ventilation. The Kaplan-Meier estimate for IMV and/or death was 15.6% in the lenzilumab arm versus 22.1% in the placebo arm. Approximately 94% of patients received dexamethasone, 72% received remdesivir, and 69% received both. In the subgroup of patients treated with both remdesivir and corticosteroids, lenzilumab improved survival without ventilation relative to placebo. In this study, lenzilumab appeared to be safe and well-tolerated, there were no serious adverse events, or SAEs, attributed to lenzilumab and no suspected unexpected serious adverse reactions reported for lenzilumab.

08:06 EDT Enerpac Tool announces Paul Sternlieb as President and CEO - Enerpac Tool Group announced that its Board of Directors has appointed Paul Sternlieb as the Company's President and Chief Executive Officer. Mr. Sternlieb has also been appointed to the Enerpac Board of Directors . Mr. Sternlieb succeeds Randy Baker, who will retire from his role as President and CEO of the Company and as a member of the Board. Mr. Sternlieb's appointment and Mr. Baker's retirement are effective October 8. Mr. Baker has agreed to remain with the company through the end of the calendar year in an advisory capacity to ensure a smooth transition. "It has been an honor to serve as CEO of Enerpac over the last five years," said Mr. Baker. "With the support of the entire team, we have made significant progress repositioning the business and driving positive change across our organization. Having navigated through the pandemic and with the Company positioned for its next phase of execution, I believe it is an appropriate time for me to step down, and I decided to do so once the right successor was found. I am very proud of all we have accomplished together and am confident in Paul's and the Enerpac team's ability to continue growing and transforming the Company following my retirement."

08:05 EDT BioHiTech Global receives order for five additional digesters from university - BioHiTech Global has received an order from an existing higher education institution client for five additional Revolution Series Sprout Digesters to enhance their four already in use. The company anticipates fulfilling these orders before the end of Q4. The digesters will serve three additional dining facilities.

08:03 EDT OptimizeRx announces findings from survey on digital solutions in diabetes - OptimizeRx announces key findings spotlighting the value of new digital engagement technologies which are poised to fill gaps in critical areas where patients and physicians need additional support in the management of type 2 diabetes according to a survey of top endocrinologists. Given the abundance of treatment options for T2D, and the various factors physicians need to take into consideration when prescribing a therapy - including patient comorbidities - pharma brand teams are investing in new digital patient engagement and adherence tools to better support both patients and providers. These digital tools can support the timely delivery of treatment options and therapy information to physicians and their patients during key decision moments, as well as extend the reach of care into patients' daily lives - delivering personalized, relevant support when it is needed, so patients have the tools and resources to manage their condition - and improve their health. In the survey, 25 top U.S. endocrinologists were asked to share the challenges they and their patients face in managing T2D, with a focus on patient communication, education, medication adherence and self-care in a challenging population. Endocrinologists face their own challenges in treating diabetes patients. Short office visits and significant amounts of information to cover with their patients mean endocrinologists aren't always able to communicate everything they need to convey to patients during the office visit, and they are limited in the support they can offer after patients have left their office. 92% of endocrinologists reported moderate to high need for support in communicating with patients about their self-care; 88% of endocrinologists reported moderate to high need for support in communicating how to access financial support/copay assistance programs; 83% of endocrinologists reported moderate to high need for support in communicating with patients about how to start making lifestyle modifications. Through the survey's results, OptimizeRx gained additional insights into areas of focus where digital and technology-enabled tools can address challenges and opportunities to improve support of patients with T2D. 54% of endocrinologists were familiar with mobile/digital co-pay cards, and 58% found them effective; 38% of endocrinologists were familiar with SMS/text message medication reminders, and 46% found them effective; 38-42% of endocrinologists were familiar with other digital tools including web-based or video educational content and motivational/inspirational SMS or email content, and many found them to be effective resources - indicating there is strong opportunity to expand the use of digital tools. The survey also notes that socioeconomic and demographic factors often play a significant role in limiting patients' abilities to make lifestyle changes or to afford their medication. Additionally, the survey reveals that as more digital and technology-enabled tools become available to support T2D patients throughout their treatment journey, opportunities abound for innovative ways to overcome modifiable barriers to medication adherence, patient engagement, and self-care. Research suggests successful management of T2D requires a combination of: access to effective medications; proper medication adherence patient lifestyle and behavioral modifications; These areas are compounded by patient belief structures, their treatment and healthcare experiences, and demographic factors. Importantly, poor medication adherence has been well documented as a central contributor to inadequate glycemic control and ensuing morbidity, healthcare utilization, and mortality. 78% of endocrinologists report patients' lack of lifestyle changes as one of their top three challenges; 62% of endocrinologists report medication costs being too high as a top three challenge; Endocrinologists estimate 51% of their patients struggle with making lifestyle changes, and 46% with affording their medication.

08:02 EDT Target announces return of Target Deal Days in October - Target announced the kick off to a joyful holiday season filled with great deals for all families. As guests prepare to shop early this year, the retailer is jumpstarting the season with the return of guest-favorite Target Deal Days in October. For three days, deals will be available online, through the Target App and, for the first time, at all Target stores, making it easy for guests to save big, no matter how they choose to shop. The retailer also is introducing a new, industry-leading Holiday Price Match Guarantee, committing to match the lowest prices at Target starting earlier than ever.

07:50 EDT U.S. Gold updates pre-feasibility study for CK Gold Project, Wyoming - U.S. Gold provided an update on its CK Gold Project located in Southeast Wyoming. The company saw considerable activity at the CK Gold Project during the summer, which is currently continuing in the fall of 2021, and expects to further advance the project to a permitting and development decision on a fast-track basis. Highlights of recent activities include: subsequent to site wetlands survey, the CK Gold Project received a non-jurisdictional determination from the U.S. Army Corps of Engineers; signed land and right-of-way agreement securing the project's footprint and access across private and onto State land; Prefeasibility Study expected by year-end 2021, currently undergoing optimization; advancing Feasibility Study fieldwork, building on PFS for anticipated FS completion by mid-2022; ongoing environmental baseline monitoring for potential filing of Mine Permit application in 2022. Management now expects the PFS will be released in Q4. Field activities progressing this summer and autumn at the CK Gold Project are intended to allow the project to move towards a full FS in 2022.

07:43 EDT Mindset identifies two additional 5-MeO-DMT-inspired lead candidates - Mindset Pharma announced that, in addition to its potential lead new chemical entity candidate, MSP-4018, the Company has identified two additional pipeline opportunities from its Family 4 compounds, MSP-4019 and MSP-4020. In preclinical studies, both compounds demonstrated strong efficacy and an improved safety profile in comparison to 5-MeO-DMT and parent compounds. Mindset's Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

07:41 EDT Wesdome Gold Mines announces results from Kiena Deep Zone - Wesdome Gold Mines announces underground exploration drilling results from the Kiena Deep Zone and initial surface exploration drilling results at the Company's 100% owned Kiena Mine Complex in Val d'Or, Quebec. On March 23, 2021, Wesdome announced the discovery of a new high grade gold zone in the footwall of the A Zone, which has been the focus of our in-fill drilling over the past several months. The Footwall Zone is interpreted as lenses of gold mineralization located within a 50 metre wide corridor adjacent to the footwall of the A2 Zone. Gold mineralization is associated with quartz +/- visible gold veins that are spatially associated with amphibolite altered komatiite, basaltic komatiite and basalt units. Because the recent drilling has been impacted by the industry wide shortage of skilled drillers, 11 holes and their wedges having reached the Footwall and A Zones since the last press release. As such, additional drilling is still required to determine the geometry of the mineralized lenses forming the corridor of the Footwall Zone. The orientation, dip and geometry of these new lenses will need to be confirmed in order to determine true widths. However, it is interpreted that the Footwall zone runs parallel to the A Zone and extends at least 300 m. Mineralization remains open laterally and down plunge.Additionally, the recent A Zone high grade drill intersections inside and outside of the current A Zone resource block model shows the potential to expand the current resource estimate. Hole 6762: 132.1 g/t Au over 7.4 m core length A Zone; Hole 6752W4: 34.3 g/t Au over 7.2 m core length A2 Zone; Hole 6762W2: 13.4 g/t Au over 16.0 m core length Footwall Zone; Hole 6762W1: 20.1 g/t Au over 9.1 m core length Footwall Zone All assays cut to 90.0 g/t Au. True widths are unknown at this time for the Footwall Zone. Initial surface drilling has focused on the Presqu'ile and Shawkey areas located northwest and southeast of the Kiena Mine, respectively. Since July 2021, two drills on barges have been testing the continuity of some gold anomalies in the Jacola Formation which host the Kiena mine. In early September 2021, a third drill was added in the Shawkey area to follow up on historical gold anomalies and newly intersected mineralization. Hole PR-20-001: 1515.0 g/t Au over 0.5 m core length; Hole PR-20-001: 23.1 g/t Au over 2.2 m core length;Hole PR-21-008: 63.9 g/t Au over 0.9 m core length; Hole SW-21-009: 20.80 g/t Au over 1.5 m core length; Hole SW-21-013: 29.40 g/t Au over 1.1 m core length. The true widths of the intersections of the Presqu'ile zones are believed to be of 70% or higher of the intersected length. Previous drilling at the Presqu'ile zones has defined a small near surface mineral resource. Eleven of the reported holes for this zone intersected gold mineralization and helped to define a steeply east-plunging trend. Future drilling will continue to test the extent of the mineralization which is near to an underground access at a vertical depth of 320 m below surface and approximately 450 m to the north. The drilling in the Shawkey area was following up on gold anomalies in historical holes and exploring untested areas along strike. Eight holes intersected a new zone called Bourgo which is perpendicular to the general northwest-southeast trend. It consists of quartz veins with very low sulphide content hosted in a komatiitic basalt unit. The northern orientation is similar to the orientation of the nearby Kiena Deep A Zones. Drilling is planned to improve the understanding of this area.

07:38 EDT VBI Vaccines announces new data and start of Covid variant study of VBI-2905 - VBI Vaccines announced positive results from multiple preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion of the ongoing clinical study of VBI's SARS-CoV-2 vaccine candidates in approximately 80 adults age 18-54. New preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta and Delta . Data also demonstrate trivalent VBI-2901 induced robust and consistent levels of immunity against the ancestral COVID-19 strain and a panel of variants including Beta, Delta, Kappa, and Lambda . First subject dosed in Phase 1b portion of ongoing study to assess VBI-2905 as a 1-dose booster in individuals previously immunized with an mRNA vaccine, and (ii) a primary 2-dose series in unvaccinated individuals Initial VBI-2905 data expected early Q1 2022, subject to speed of enrollment. Bill Cameron, M.D., Medical Director of Clinical Research at the Ottawa Hospital Research Institute, Infectious Disease Specialist at The Ottawa Hospital, Professor at the University of Ottawa, and Principal Investigator of the ongoing Phase 1a/1b study, commented: "The significant number of COVID-19 infections on a global scale contributes to increasing numbers of mutations and thus emergence of new viral variants. Some are associated with increased transmissibility, like Alpha and Delta variants, and some with escape from natural or vaccine acquired immunity, like Beta, Mu, Lambda, and Kappa variants. These vaccine-escape variants have shown to be associated with decreased immunogenicity of licensed COVID-19 vaccines, which are based on expression of various forms of the S protein using the unmutated reference sequence from the ancestral strain. Development of an effective booster strategy or new vaccines that are able to broaden protection against more than one variant will be important for the public health management of COVID-19. In-line with that effort, we look forward to seeing the data from this next phase of VBI's clinical study."

07:35 EDT TG Therapeutics announces data presentations from ULTIMATE I, II Phase 3 trials - TG Therapeutics announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis, at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held virtually October 13 - 15, 2021. Regular abstracts are now available through the ECTRIMS platform and late-breaking abstracts will be accessible on October 13, 2021. Michael Weiss, Chairman and CEO of TG Therapeutics stated, "We are pleased to have two abstracts accepted for presentation at the upcoming ECTRIMS congress, including an oral presentation, showcasing data from the ULTIMATE I & II Phase 3 trials. While much of the data have been presented previously, we look forward to sharing some additional analyses which we believe further reinforce the potential value of ublituximab to treat patients with RMS." Mr. Weiss continued, "We look forward to the ECTRIMS congress and hope you all can join us on October 14 to review the data and hear from key opinion leaders."

07:34 EDT Papa John's in domestic development deal with Sun Holdings - Papa John's International announced it has signed its largest domestic franchisee development agreement in the company's history with top U.S. franchisee operator Sun Holdings . Under the terms of the deal, Sun Holdings will oversee the opening of 100 new stores in high-growth markets across Texas by 2029. The partnership is another sign of Papa John's accelerating development momentum, as both current and prospective franchisees show strong interest in opening new locations around the world.

07:32 EDT Dollar Tree increases share repurchase program by $1.05B to $2.5B - Dollar Tree reported that its board of directors has increased the company's share repurchase authorization by $1.05B to an aggregate amount of $2.5B, including approximately $1.45B available for repurchases under the board's previous repurchase authorization approved on March 2.

07:20 EDT ADC Therapeutics joint venture doses first patient in Zynlonta study - Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics, announced the first patient has been dosed with Zynlonta in a pivotal Phase 2 clinical trial in patients with relapsed or refractor diffuse large B-cell lymphoma, or DLBCL, in China. In April, Zynlonta was granted accelerated approval by the FDA as the first and only CD19-targeted antibody drug conjugate, or ADC, as a single-agent treatment for adult patients with r/r DLBCL after two or more lines of systemic therapy. This local pivotal study mirrors ADC Therapeutics' ongoing global pivotal Phase 2 clinical trial of Zynlonta and its results are intended to support the potential registration of Zynlonta in China.

07:16 EDT Enbridge reports substantial completion of Line 3 Replacement Project - Enbridge announced the achievement of a major milestone with the substantial completion of the Line 3 Replacement Project and the establishment of an in-service date of October 1. This step marks the full replacement of the entire 1,765-kilometre/1,097-mile-long pipeline from Edmonton, AB. to Superior, WI. With new state-of-the-art, thicker-walled pipe, its completion ensures a safe, reliable supply of North American crude oil to U.S. refineries, helping fuel the quality of life for millions of people.

07:12 EDT Calibre Mining announces update on drilling program at Limon Complex - Calibre Mining is pleased to provide an update of the Company's 2021 resource expansion and discovery drilling program, highlighting drilling completed at high-grade deposits and targets within the Company's producing Limon Mine Complex. Atravesada Underground: 9.02 g/t Au over 3.0 metres Estimated True Width from 343.6 metres; 6.39 g/t Au over 6.2 metres ETW from 241.1 metres; 4.27 g/t; Au over 4.2 metres ETW from 360.4 metres. Tigra - beyond the reserve pit shell: 6.82 g/t Au over 4.3 metres ETW from 285.9 metres; 5.28 g/t Au over 4.8 metres ETW from 251.4 metres; 12.17 g/t Au over 2.2 metres ETW from 284.8 metres; 7.12 g/t Au over 2.0 metres ETW from 315.7 metres. New Gold Zone within the Limon Complex: Portal Target: 5.75 g/t Au over 2.3 metres ETW from 115.2 metres; 2.77 g/t Au over 4.1 metres ETW from 66.8 metres; 1.68 g/t Au over 18.6 metres ETW from 40.1 metres. Drilling at the Atravesada deposit continues to return high-grade intercepts over significant widths. Importantly, drilling down plunge along the central ore shoot has returned multiple high grade gold intercepts up to 100 metres below the limits of the currently reported underground indicated resource. Recent drilling at Tigra provides further confirmation of the potential to delineate additional high-grade resources along the main ore shoot as it extends below the current open pit probable reserve. The reserve contains 547,000 tonnes averaging 4.93 g/t Au and 87,000 ounces contained gold1. Additional inferred resources below the open pit reserve include 221,000 tonnes averaging 7.02 g/t Au and 50,000 ounces contained gold1. Drilling along strike and down plunge of the principal ore shoots at Panteon and Santa Pancha 1 has returned additional drill intercepts consistent with the high-grade shoots already delineated at each deposit. The north-south trending Portal vein lies approximately one kilometre north of Atravesada. First pass drilling intersected near surface mineralization below historic trenching by B2Gold that returned 74.3 g/t Au over 3.8 metres and 9.6 g/t over 2.0 metres1. Exploration drilling will continue to test the extent and continuity of gold mineralization both laterally and down dip along the Portal vein.

07:12 EDT Targa Resources releases Sustainability Report for 2020 - Targa Resources announced that its Sustainability Report for 2020 is now available on the company's website. "The report advances Targa's sustainability disclosures and provides a review of Targa's performance against various environmental, social, and governance topics that are important to our industry," the company said. Highlights of Targa's 2020 Sustainability Report include the following: achieved a 34% decrease in flaring volumes from emissions events and a 16% decrease in the total number of flaring incidents; developed a goal to reduce methane intensity to 0.08% for gathering and boosting segment and 0.11% for the processing segment by 2025; reduced total recordable injury rate by more than 35% and days away, restricted, or transferred incident rate by more than 41% between 2017 and 2020; implemented a new mobile safety app for reporting near misses and other hazards; exported approximately 4.6B gallons of liquefied petroleum gas globally; formed a new team focused on renewable power, carbon capture, and other business opportunities; continued to build a diverse workforce - 29% of workforce was from traditionally under-represented racial or ethnic groups, 24% of leaders across Targa were women; established a Board-level Sustainability Committee to oversee management's implementation of strategy to integrate sustainability into various business activities to create long-term stakeholder value.

07:10 EDT Verano Holdings to open MUV Dispensary in Pinellas Park - Verano Holding announced the opening of its newest MundefinedV dispensary located at 7263 Park Boulevard North, Pinellas Park, Florida. At 10:00 a.m. local time today, the dispensary will open and begin seeing patients, with a grand opening planned for Friday at 10:00 a.m., pending all required approvals. Verano's 38th MundefinedV Florida dispensary is centrally located on the Pinellas Peninsula, in one of the state's most densely populated counties. The new MundefinedV storefront is accessible from both Park Boulevard North and Belcher Road, as well as from 74th Street North through neighboring businesses. Patients can, based on preference, order ahead at muvfl.com for express pickup in-store, or take advantage of home delivery service that is available across the state within a 20-mile radius of MundefinedV storefronts.

07:08 EDT Taysha Gene Therapies gets orphan drug designation from EC for TSHA-101 - Taysha Gene Therapies announced that it has been granted orphan drug designation from the European Commission for TSHA-101, an AAV9-based bicistronic gene replacement therapy in development for GM2 gangliosidosis, also called Tay-Sachs or Sandhoff disease. "GM2 gangliosidosis is a fatal neurodegenerative disease caused by deficiency in the lysosomal enzyme beta-hexosaminidase A, also known as Hex A. The prognosis is devastating, with infantile forms often leading to death within the first four years of life and juvenile onset patients rarely surviving beyond mid-teens," said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha. "Residual Hex A activity correlates with the severity of GM2, and based on our understanding of this correlation, small increases in Hex A activity are likely to lead to significant improvements in clinical outcomes and quality of life. Based on dose-dependent improvements in survival in preclinical models, we are highly encouraged that our novel bicistronic gene therapy approach with TSHA-101 has the potential to be a life changing therapy for patients suffering from this rapidly progressive disorder with no current treatment options." TSHA-101 is an investigational gene therapy that delivers the HEXA and HEXB genes that make up the beta-hexosaminidase A enzyme. The two genes are driven by a single promoter within the AAV9 bicistronic vector ensuring that the 2 sub-units of Hex A are produced in a one-to-one ratio within each cell, which is important to ensure efficient production of the transgene. TSHA-101 is the first and only bicistronic vector currently in clinical development and has been granted Orphan Drug and Rare Pediatric Disease designations by the U.S. Food and Drug Administration, FDA. TSHA-101 is administered intrathecally and is currently being evaluated in a single arm, open-label Phase 1/2 clinical trial for the treatment of infants with GM2 gangliosidosis sponsored by Queen's University. Preliminary clinical safety and biomarker data are expected by year-end 2021.

07:07 EDT Evogene's Lavie Bio, United Agronomy announce distribution agreement - Lavie Bio, a subsidiary of Evogene, and United Agronomy, a full-service retailer of crop inputs, including seeds, inoculants, fertilizers, and chemicals, announce that they have entered into a distribution agreement, initially for spring wheat, for LAV.211, a Lavie developed inoculant. Under the terms of the agreement, LAV.211 will be distributed through UA's marketing channels in North Dakota, USA as part of UA's robust product offering, which includes top certified seed varieties and preferred seed treatments. The parties expect that initial marketing and commercialization activity will target the 2022 spring wheat season, in North Dakota.

07:06 EDT Walker & Dunlop structures $164M in financing for The Goodtime Hotel - Walker & Dunlop, Inc. announced today that it structured $164M in financing for The Goodtime Hotel, located in Miami Beach, Florida. The team arranged a three-year, interest-only bridge loan with two one-year extension options on behalf of their client, Dreamscape.

07:04 EDT Orthofix sees Q3 low single-digit revenue growth over Q3 last year - Orthofix Medica provided a business update. The Company has experienced the impact of higher than expected volumes of deferred or rescheduled elective procedures resulting from hospital procedural restrictions, both in the U.S. and internationally, associated with the recent surge in COVID-19 Delta variant cases. As a result, the Company expects revenue growth for the third quarter of 2021 to be consistent with, or a low single-digit increase over, third quarter 2020 revenue. "Throughout 2021, we have seen the positive results of our key strategic initiatives, despite the ongoing uncertainty associated with COVID-19," said Orthofix President and Chief Executive Officer Jon Serbousek. "While the overall elective procedure market has again taken a downward trend as a result of the pandemic, we are confident in our vision and ability to accelerate the growth of our business." Mr. Serbousek continued, "We remain dedicated to delivering innovative, high-value solutions to physicians to improve patient mobility. Over the near term, we are focused on driving the adoption of the M6-C artificial cervical disc, the FITBONE limb lengthening system, and our recently bolstered 3D-printed titanium spinal interbody portfolio. In addition, we will continue to invest for growth, in particular with the expansion of our biologics portfolio and the development of innovative new bone growth therapy products."

07:03 EDT Fortress Biotech announces AstraZeneca to fully acquire Caelum for $150M - Fortress Biotech (FBIO) and a company it founded, Caelum Biosciences, announced that AstraZeneca's (AZN) Alexion notified Caelum that it has exercised its option to acquire Caelum, pursuant to the Development, Option and Stock Purchase Agreement in place between Fortress, Caelum, Alexion and the other parties thereto. In addition, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired in connection with such acquisition. Expiration of the waiting period under the HSR Act satisfies one of the conditions precedent for consummation of the acquisition. Under terms of the DOSPA, upon closing of the acquisition, which is expected to take place on October 5, 2021, Alexion will purchase all of the outstanding shares of Caelum and will pay Caelum the agreed option exercise price of approximately $150M. Distributions will be made to all existing Caelum stockholders. The agreement also provides for additional potential payments to Caelum stockholders totaling up to $350M, payable upon the achievement of regulatory and commercial milestones. Fortress is eligible to receive approximately 43% of all proceeds from the transaction. "The acquisition of Caelum is a positive development and monetization opportunity for our shareholders, while validating the Fortress business model," said Lindsay Rosenwald, M.D., Fortress' Chairman, President and Chief Executive Officer. "We believe in CAEL-101's potential to be a best-in-class treatment for AL amyloidosis and look forward to the continued progression of CAEL-101 in the CARES Phase 3 clinical program under the leadership of the renowned team at Alexion." The Cardiac Amyloid Reaching for Extended Survival clinical program is evaluating CAEL-101, and enrollment is ongoing in two parallel Phase 3 studies - one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease. The company also has a Phase 2 clinical study that is evaluating the safety and tolerability of CAEL-101 in patients with AL amyloidosis.

07:02 EDT TransMedics says FDA grants premarket approval of OCS Liver System - TransMedics Group announced that the U.S. FDA has granted premarket approval of its OCS Liver System for use with organs from donors after brain death and after circulatory death. The OCS Liver System is indicated for the preservation and monitoring of hemodynamics and metabolic function which allows for ex-vivo assement of liver allografts from DBD and DCD donor livers. This indication is based on the results of the OCS Liver PROTECT Trial.

06:49 EDT Asbury Automotive to acquire Larry H. Miller Dealerships, Total Care Auto - Asbury Automotive Group entered into a definitive agreement with Larry H. Miller Group of Companies to acquire Larry H. Miller Dealerships, the eighth largest dealer group in the U.S., and Total Care Auto, Powered by Landcar. The aggregate purchase price of $3.2B includes approximately $740M of real estate. The transaction is expected to close in the fourth quarter of 2021 and is subject to automobile factory approvals and other customary closing conditions. The EBITDA for the twelve months ended June 30, 2021 of these acquired entities is approximately $360M, which includes day-one cost savings. Asbury has secured committed bridge financing in support of the acquisition, which it expects to replace with a combination of permanent debt and equity financing prior to closing. The equity portion of the permanent financing is currently expected to be approximately $600M. Although the transaction is initially expected to take Asbury above its targeted net leverage range of 3.0x, Asbury believes that it can de-lever to near 3.0x over the next 18-24 months given the highly accretive nature of the deal combined with strong free cash flow generation. The acquisition of these entities, assuming a fourth quarter of 2021 closing date and equity financing of $600M, is expected to be approximately 14% accretive to 2022 earnings per share with 2024 EPS accretion expected to be approximately 20%. Asbury also has several other strategic acquisitions under contract, which also align with Asbury's culture and customer centric model, that are expected to add approximately $900 million in additional annualized revenues. These acquisitions are expected be funded using existing cash on hand and existing credit facilities. These additional acquisitions are expected to drive total, inclusive of Larry H. Miller Dealerships, TCA, and the additional acquisitions under contract, 2022 EPS accretion to approximately 20% and 2024 EPS accretion to approximately 28%.

06:41 EDT PTK Acquisition Corp shareholders approve combination with Valens - In a regulatory 8-K filing, the company states that its shareholders have voted in favor "to adopt a proposal to adopt and approve the Business Combination Agreement, dated as of May 25, 2021, by and among PTK, Valens Semiconductor Ltd., a company organized under the laws of the State of Israel and Valens Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Valens, pursuant to which Merger Sub will merge with and into PTK, with PTK surviving the merger as a wholly-owned subsidiary of Valens."

06:38 EDT Adagio Therapeutics' ADGO shows safety and efficacy data in COVID-19 trial - Adagio Therapeutics announced new data from the company's COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular dose given as a single injection that is being evaluated in the company's ongoing global Phase 2/3 treatment and prevention clinical trials will be presented at the Infectious Disease Society of America's IDWeek from Sept. 29 - Oct. 3. In addition, Adagio will present a subset of the ADG20 Phase 1 data at the 19th Annual Discovery on Target Conference on Sept. 30. Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics, immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. ADG20 was well tolerated with no study drug-related adverse events, serious AEs, or injection-site or hypersensitivity reactions reported.

06:33 EDT Amicus, Arya Sciences Acquisition Corp IV to form genetic medicine company - Amicus Therapeutics (FOLD) announced its intent to launch a next-generation genetic medicine company, Caritas Therapeutics, through a definitive business combination agreement pursuant to which the Amicus gene therapy business will be acquired by ARYA Sciences Acquisition Corp IV (ARYD), a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors. The transaction will result in two independent publicly traded companies with attractive stand-alone investment profiles. Amicus will become the largest shareholder in Caritas with a ~36% ownership stake (assuming no redemptions by ARYA's shareholders) and retain co-development and commercialization rights to the Fabry and Pompe gene therapy programs as well as negotiation rights on select future muscular dystrophy programs. Upon consummation of the business combination, current Amicus Chairman and Chief Executive Officer John F. Crowley will lead Caritas as Chairman and Chief Executive Officer and will become the Chairman Emeritus and Chief Strategic Advisor for Amicus. Current Amicus President and Chief Operating Officer Bradley Campbell will be named as Chief Executive Officer of Amicus. Amicus expects to incur charges related to the transaction during the reporting periods preceding the separation and does not otherwise expect this to impact Amicus' financial guidance for 2021. In connection with the closing of the transaction, in addition to its renaming, ARYA IV will redomicile as a Delaware corporation and its common stock is expected to be listed on Nasdaq under the ticker symbol "SPES", the Latin word for hope. In addition to the approximately $150 million held in ARYA IV's trust account, assuming no redemptions are effected, a group of leading global investors has committed to participate in the transaction through a common stock private investment in public equity (PIPE) of approximately $200 million at $10 per share. Investors in the PIPE include Perceptive Advisors, Redmile Group, Bain Capital Life Sciences, Invus, Avoro Capital Advisors, Surveyor Capital, Deerfield Management Company, Wellington Management and Sphera Healthcare. In connection with the business combination, Amicus will also invest $50 million in cash in Caritas in exchange for additional equity in Caritas. Together, Caritas is expected to receive proceeds of approximately $400 million at the closing of the transactions, assuming no redemptions are effected. Proceeds of the business combination and the PIPE are expected to be used to advance development of the Caritas gene therapy pipeline, discovery work, growth across its scientific teams and to support general corporate activities (including payment of certain transaction expenses). A condition to closing of the business combination transaction is that these cash proceeds are no less than $300 million in total. The boards of directors of both Amicus and ARYA IV have approved the proposed transaction. Completion of the transaction, which is expected in the fourth quarter of 2021 or early 2022, is subject to approval of ARYA IV's shareholders, delivery of the minimum $300 million in cash proceeds, and the satisfaction or waiver of certain other customary closing conditions.

06:32 EDT AstraZeneca exercises option to fully acquire Caelum Biosciences for $150M - The company states: "AstraZeneca's Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody for the treatment of light chain amyloidosis. CAEL-101 is currently being evaluated in the Cardiac Amyloid Reaching for Extended Survival Phase III clinical program in combination with standard-of-care therapy in AL amyloidosis. Two parallel Phase III trials in patients with Mayo stage IIIa disease and in patients with Mayo stage IIIb disease respectively are ongoing. In 2019 Caelum and Alexion first entered into a collaboration whereby Alexion acquired a minority equity interest and an exclusive option to acquire the remaining equity in Caelum. Alexion currently consolidates Caelum and reflects a non-controlling interest of $150M. Upon closing the acquisition, which is expected to take place on 5 October 2021, Alexion will pay Caelum the agreed option exercise price of approximately $150M, with the potential for additional payments of up to $350M upon achievement of regulatory and commercial milestones." Reference Link

06:13 EDT Diageo opens first carbon neutral whiskey distillery in North America - Diageo announced Tuesday that it has opened its first carbon neutral distillery in Lebanon, Kentucky. The site will support the local community with 30 full-time jobs while also sourcing 100% non-GMO corn locally, the comp[any said in a statement, adding that the 72,000 square-foot facility has the capacity to produce up to 10 million proof gallons per year and has begun distilling Bulleit Bourbon using electrode boilers that are powered by 100% renewable electricity throughout the cooking, distillation, and dry house processes. Bulleit is the first and lead brand being produced at the Lebanon Distillery -and supplements existing production at the nearby Bulleit Distilling Co. in Shelbyville, Kentucky, Diageo said. These technologies will allow the distillery to avoid approximately more than 117,000 metric tons of carbon emissions annually, the equivalent of taking more than 25,000 cars off the road for a year, it further stated.

06:03 EDT DexCom's G6 CGM System now covered in Manitoba for Type 1 diabetes - Dexcom reported that people with type 1 diabetes who are 25 years of age or under may now be eligible for provincial coverage of the Dexcom G6 CGM System through Manitoba Health and Seniors Care. Manitoba joins British Columbia, Saskatchewan, Yukon and Quebec in offering public coverage of CGM systems under provincial health plans. The Non-Insured Health Benefits Program also recently announced coverage for First Nations and Inuit children. As part of the Manitoba Health coverage program, users will now be able to order and pick up their Dexcom CGM supplies through their local pharmacy.

06:01 EDT Akamai to acquire Guardicore for $600M - Akamai announced it has entered into a definitive agreement to acquire Tel Aviv, Israel-based Guardicore. Under terms of the agreement, Akamai has agreed to acquire all of the outstanding equity of Guardicore for approximately $600M, after giving effect to expected purchase price adjustments. The closing of the transaction, which is subject to customary closing conditions, is expected to occur in Q4. For FY22, the Guardicore acquisition is anticipated to provide about $30M-$35M in revenue, and Akamai's non-GAAP operating margin is anticipated to be in the range of approximately 29%-30%. The company's non-GAAP operating margin is expected to return to at least 30% for fiscal year 2023. On its next quarterly call currently scheduled for November 2, the company plans to provide Q3 financial results and FY21 financial guidance including any expected impact from Guardicore.

05:29 EDT Peak Fintech Group voluntarily withdraws Form 40-F - Peak Fintech Group announced that it has voluntarily withdrawn its Form 40-F filed with the U.S. Securities and Exchange Commission while it works to comply with recent disclosure guidance provided by the SEC for companies either based in China or with the majority of their operations in China. Without an effective Form 40-F filed with the SEC to register the company's common shares under Section 12 of the Securities Exchange Act of 1934, the company's common shares will no longer be listed on the Nasdaq Capital Market as of immediately prior to market open on Thursday September 30. Peak's application to list on the Nasdaq was made under the Multijurisdictional Disclosure System, or MJDS, which was jointly adopted by the SEC and the Canadian Securities Administrators. The Company has been cooperating with the SEC and plans to submit an amended Form 40-F that highlights the concerns referenced in the guidance as soon as practicable. Peak will keep Nasdaq informed of its progress with the amended Form 40-F, which Peak hopes will lead to having a revised Form 40-F be declared effective by the SEC on an expedited basis so that the company's common shares will be listed on the Nasdaq as soon as possible.

05:21 EDT Atara Biotherapeutics to present new ATA188 data at ECTRIMS - Atara Biotherapeutics announced the upcoming full release of new translational data and two-year open-label extension, or OLE, clinical data from the study of ATA188 in progressive multiple sclerosis, or MS. The findings will be presented as an ePoster at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS, taking place virtually October 13-15. The presentation includes new imaging data on magnetization transfer ratio, or MTR, a biomarker of myelination status that may be tied to improvements in expanded disability status scale as seen with ATA188. As reported in the full abstract, the data demonstrate that ATA188 continues to be well-tolerated. Of 24 patients evaluated for efficacy in the initial 12-month period, 18 chose to participate in the OLE and as of April, have been followed for up to 33 months. Nine patients met sustained disability improvement, or SDI, criteria, a composite scale combining confirmed improvement in either the EDSS score or timed 25-foot walk test in the initial 12-month period or in the OLE. Of these nine patients, seven achieved SDI via sustained EDSS improvement. Eight patients that achieved SDI at any point in the study participated in the OLE. A relationship between dose-escalation and increasing clinical response was observed, with a higher proportion of patients achieving SDI at higher doses. No grade greater than3 adverse events (AE), dose-limiting toxicities, cytokine release syndrome, graft versus host disease, or infusion-related reactions were observed. Changes in MTR, reflecting myelination status, may provide insights into the mechanism of EDSS improvement in clinical assessment of ATA188 and was assessed in all patients. At 12 months, the seven patients achieving SDI by EDSS showed increases in MTR versus those that did not have EDSS improvement. The increase in MTR suggests increased myelin density in the central nervous system of patients receiving ATA188. Updated OLE data of up to 33 months follow-up continue to support the durability of disability improvement following ATA188 treatment. Of the eight patients who achieved SDI and entered the OLE, seven maintained SDI at all subsequent timepoints. One patient with secondary progressive multiple sclerosis, or SPMS, achieved SDI at 15 months and experienced a non-treatment related relapse at 18 months, occurring approximately six months after the last ATA188 dose, and elected to discontinue the study. Further detail on the MTR data, as well as updated safety and efficacy data for up to 39 months follow-up in the OLE will be presented on October 13 in the ePoster presentation. In a separate ePoster, Atara will also present encore data profiling and evaluating the functionality and proliferation potential of ATA188 following antigen exposure. This analysis of ATA188 lots produced from diverse human leukocyte antigen, or HLA, donors demonstrates a manufacturing process showing consistent functional activation and productive effector responses.

05:13 EDT Fortuna Silver Mines to proceed with construction of open pit mine at Seguela - Fortuna Silver Mines announced that the board has made a decision to proceed with the construction of an open pit mine at the Seguela gold Project in Cote d'Ivoire. The company is ready to immediately commence construction with long lead items procured, and development teams established on the ground. In July, Fortuna completed the acquisition of Roxgold which was advancing the Seguela Project. The updated Seguela Project total initial capital investment is $173.5M. A total of $11.5M of this amount has previously been approved by the board for early works items. The anticipated construction schedule is approximately 20 months, with ramp-up to name plate capacity expected in the third quarter of 2023.

05:09 EDT Equinix chosen by i3D.net to support gaming platform - Equinix has been chosen by application hosting and infrastructure service provider i3D.net to support its global gaming platform. Acquired by one of the world's largest game publishers, Ubisoft, i3D.net provides a low-latency network and has partnered with Equinix to gain proximity to its end users following an uptick in activity.